In
silico clinical trials use computer simulation and models to predict drug efficacy
and safety. They help reduce time and costs associated with drug development
and testing. Key advantages include improved predictions of pharmacokinetics
and toxicity with less risk to humans in early stages of research.
The
global In Silico Clinical Trials Market is estimated to be valued at US$ 3,410.4 Mn in 2023 and is expected
to exhibit a CAGR of 7.9% over the
forecast period 2023 to 2030, as
highlighted in a new report published by Coherent Market Insights..
Market key trends:
Advancement
in technology has been a key driver for the growth of in silico clinical trials
market. Adoption of artificial intelligence and machine learning has enabled
developers to build complex biological models that help simulate human
physiology and predict drug behavior in a human body with higher accuracy.
Increased computational power allows processing of large real-world datasets to
train algorithms. This has improved the predictive capabilities of in silico
models. Researchers are now able to virtually replicate pathophysiology of
various disease conditions and closely mimic human trials in silico with
integration of multi-omics data and patient-derived models. Further
technological advancements are expected to enhance predictive performance of in
silico platforms and help accelerate drug development process significantly
over the forecast period.
Segment Analysis
The global In Silico Clinical Trials Market is segmented by application,
therapeutic area, end use, and geography. By application, the market is dominated
by the preclinical trials segment as it helps in cost-saving for pharmaceutical
companies by eliminating the risk of harmful effects on humans at the early
discovery stages. By therapeutic area, the oncology segment holds the major
market share due to high adoption of in silico trial methods for new cancer
drug discovery. By end use, pharmaceutical and biotechnology companies
extensively utilize in silico clinical trials solutions for efficient drug
R&D with lower investments compared to physical trials.
Key Takeaways
Regional analysis: North America holds the highest share in the In Silico
Clinical Trials market mainly due to increasing investments by pharmaceutical
giants for advanced drug discovery techniques. The region has well-established
healthcare IT infrastructure providing growth opportunities to key players.
Additionally, favorable government initiatives are boosting adoption of novel
technologies including virtual clinical trials in the region.
Key players: Key players operating in the In Silico Clinical Trials market
include Abzena Ltd., Clarivate, Immunetrics Inc., GNS Healthcare, Dassault
Systemes, Evotec, Novadiscovery, Insilico Medicine Inc., and InSilicoTrials
Technologies, among others. Abzena specializes in biologics engineering for the
development of bio therapeutics across diverse modalities. Clarivate provides
scientific and clinical research data solutions and services.
Immunetrics leverages artificial intelligence techniques for advanced drug
development through virtual clinical trials. GNS Healthcare offers end-to-end
simulation platforms for biosciences research. Dassault Systemes provides
bioconvergence platform powered by virtual replicas of biological functions.
Novadiscovery focuses on developing accelerated clinical trial simulations
technology for therapeutics and vaccines. Insilico Medicine applies latest AI
techniques like generative adversarial networks for target identification, drug
discovery and trial optimization.
Get
more insights on this topic:
Comments
Post a Comment